Sex differences in glioblastoma response to treatment: Impact of MGMT methylation


Gino Cioffi 1, Kristin A Waite 1, Mantas Dmukauskas 1, Michael Glantz 2, Sonikpreet Aulakh 3, Theodore Nicolaides 4, Soma Sengupta 5, Joanne Xiu 4, Jill S Barnholtz-Sloan 1 6

It has been established that glioblastoma (GBM) survival differs by sex, with females having a significant survival advantage.1 Another prognostic factor associated with GBM survival is O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, associated with sensitivity to alkylating chemotherapy, such as temozolomide (TMZ), and improved survival.2,3MGMT methylation status impacts treatment patterns for GBM. Studies suggest that patients with unmethylated tumors should receive only radiotherapy.4 Here, we investigate, utilizing a large real-world data set, the impact of MGMT methylation status on sex-specific survival for different GBM treatment patterns.

External Link